Provenge (sipuleucel-T) is an immunotherapy treatment specifically designed for prostate cancer. It is an autologous cellular immunotherapy, meaning it uses the patient's own immune cells to fight the cancer. This treatment is primarily used for patients with metastatic castration-resistant prostate cancer (mCRPC).
